Matt Bodenstein is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group where he advises a diverse range of clients in the chemical, pharmaceutical, food science, material science, and biotechnology spaces. He has been recognized by his clients and peers as a leading patent strategist and is well-known for his thoughtful and creative approaches to obtaining business-critical patents.
Matt’s practice includes assisting clients with creating and managing strategic patent portfolios, managing complex and high priority patent prosecution (including “Track 1” applications), conducting and managing complex due diligence investigations in connection with potential investments, acquisitions, and licensing opportunities, and rendering freedom to operate, validity, and non-infringement opinions.
In addition to his focus on pure patent matters, Matt regularly helps clients negotiate term sheets, license agreements, and other strategic transactions.
Prior to joining Sterne Kessler, Matt was Intellectual Property Counsel for the former Medicis Pharmaceutical Corp., and an associate and patent agent in the IP Group of an AmLaw 100 law firm.
Before becoming a lawyer, Matt worked in the CNS Medical Chemistry group at Pfizer, Inc. and the Process Research and Development Group at Merck & Co., Inc.
Matt earned his J.D., cum laude, from Temple University Beasley School of Law, and his M.S. and B.A. degrees in Chemistry, from the University of Pennsylvania.
Outside of work, Matt can often be found walking his Great Pyrenees/hound mix, Ripley, relaxing with his family at a Nats or DC United game, or cranking away on his bike (look for him on Zwift!).
- IAM Strategy 300, “Global Leaders Guide” (2023 - 2021)
- IAM Strategy 300, "A Guide to the World's Leading IP Strategists" (2022 - 2021)